Literature DB >> 30804049

Proteomic Maps of Human Gastrointestinal Stromal Tumor Subgroups.

Yu Liu1, Zhigui Li1, Zhiqiang Xu1, Xiuxiu Jin1, Yanqiu Gong1, Xuyang Xia1, Yuqin Yao1, Zhaofen Xu2, Yong Zhou1, Heng Xu1, Shuangqing Li1, Yong Peng1, Xiaoting Wu3, Lunzhi Dai4.   

Abstract

Gastrointestinal stromal tumor (GIST) is a common sarcoma of gastrointestinal tract (GIT) with high metastatic and recurrence rates, but the proteomic features are still less understood. Here we performed systematic quantitative proteome profiling of GIST from 13 patients classified into very low/low, intermediate and high risk subgroups. An extended cohort of GIST (n = 131) was used for immunohistochemical validation of proteins of interest. In total, 9177 proteins were quantified, covering 55.9% of the GIT transcriptome from The Human Protein Altas. Out of the 9177 quantified proteins, 4930 proteins were observed in all 13 cases with 517 upregulated and 187 downregulated proteins in tumorous tissues independent of risk stage. Pathway analysis showed that the downregulated proteins were mostly enriched in metabolic pathway, whereas the upregulated proteins mainly belonged to spliceosome pathway. In addition, 131 proteins showed differentially expressed patterns among GIST subgroups with statistical significance. The 13 GIST cases were classified into 3 subgroups perfectly based on the expression of these proteins. The intensive comparison of molecular phenotypes and possible functions of quantified oncoproteins, tumor suppressors, phosphatases and kinases between GIST subgroups was carried out. Immunohistochemical analysis of the phosphatase PTPN1 (n = 117) revealed that the GIST patients with high PTPN1 expression had low chances of developing metastasis. Collectively, this work provides valuable information for understanding the inherent biology and evolution of GIST.
© 2019 Liu et al.

Entities:  

Keywords:  Clinical proteomics; Diagnostic; GIST; Gastrointestinal disease; High Throughput Screening; Immunohistochemistry; Mass Spectrometry; PPP2CB; PTPN1; Protein Phosphatases*; Quantitative proteomics; risk classification

Mesh:

Substances:

Year:  2019        PMID: 30804049      PMCID: PMC6495251          DOI: 10.1074/mcp.RA119.001361

Source DB:  PubMed          Journal:  Mol Cell Proteomics        ISSN: 1535-9476            Impact factor:   5.911


  54 in total

1.  PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Authors:  Laurent Lessard; David P Labbé; Geneviève Deblois; Louis R Bégin; Serge Hardy; Anne-Marie Mes-Masson; Fred Saad; Lloyd C Trotman; Vincent Giguère; Michel L Tremblay
Journal:  Cancer Res       Date:  2012-01-26       Impact factor: 12.701

2.  RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells.

Authors:  Daojing Wang; Jing Huang; Zhi Hu
Journal:  Mol Cell Proteomics       Date:  2011-11-15       Impact factor: 5.911

Review 3.  Targeting the EGFR signaling pathway in cancer therapy.

Authors:  Parthasarathy Seshacharyulu; Moorthy P Ponnusamy; Dhanya Haridas; Maneesh Jain; Apar K Ganti; Surinder K Batra
Journal:  Expert Opin Ther Targets       Date:  2012-01-12       Impact factor: 6.902

4.  Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.

Authors:  S Hirota; K Isozaki; Y Moriyama; K Hashimoto; T Nishida; S Ishiguro; K Kawano; M Hanada; A Kurata; M Takeda; G Muhammad Tunio; Y Matsuzawa; Y Kanakura; Y Shinomura; Y Kitamura
Journal:  Science       Date:  1998-01-23       Impact factor: 47.728

5.  CDH1-related hereditary diffuse gastric cancer syndrome: clinical variations and implications for counseling.

Authors:  Irma Kluijt; Ester J M Siemerink; Margreet G E M Ausems; Theo A M van Os; Daphne de Jong; Joana Simões-Correia; J Han van Krieken; Marjolijn J Ligtenberg; Joana Figueiredo; Els van Riel; Rolf H Sijmons; John T M Plukker; Richard van Hillegersberg; Evelien Dekker; Carla Oliveira; Annemieke Cats; Nicoline Hoogerbrugge
Journal:  Int J Cancer       Date:  2011-10-23       Impact factor: 7.396

6.  Prediction of clinical outcome with microarray data: a partial least squares discriminant analysis (PLS-DA) approach.

Authors:  Miguel Pérez-Enciso; Michel Tenenhaus
Journal:  Hum Genet       Date:  2003-02-27       Impact factor: 4.132

Review 7.  RNA mis-splicing in disease.

Authors:  Marina M Scotti; Maurice S Swanson
Journal:  Nat Rev Genet       Date:  2015-11-23       Impact factor: 53.242

8.  Protein phosphatase and TRAIL receptor genes as new candidate tumor genes on chromosome 8p in prostate cancer.

Authors:  Max Hornstein; Michèle J Hoffmann; Adrian Alexa; Masanori Yamanaka; Mirko Müller; Volker Jung; Jörg Rahnenführer; Wolfgang A Schulz
Journal:  Cancer Genomics Proteomics       Date:  2008 Mar-Apr       Impact factor: 4.069

9.  The predictive value and the correlation of peripheral absolute monocyte count, tumor-associated macrophage and microvessel density in patients with colon cancer.

Authors:  Zhigui Li; Zhaofen Xu; Yuqian Huang; Rui Zhao; Yaping Cui; Yong Zhou; Xiaoting Wu
Journal:  Medicine (Baltimore)       Date:  2018-05       Impact factor: 1.889

Review 10.  Emerging functions of SRSF1, splicing factor and oncoprotein, in RNA metabolism and cancer.

Authors:  Shipra Das; Adrian R Krainer
Journal:  Mol Cancer Res       Date:  2014-05-07       Impact factor: 5.852

View more
  3 in total

Review 1.  Proteomic research in sarcomas - current status and future opportunities.

Authors:  Jessica Burns; Christopher P Wilding; Robin L Jones; Paul H Huang
Journal:  Semin Cancer Biol       Date:  2019-11-10       Impact factor: 15.707

2.  THZ1 targeting CDK7 suppresses c-KIT transcriptional activity in gastrointestinal stromal tumours.

Authors:  Jianyi Sun; Qiang Zhang; Xiangfei Sun; Anwei Xue; Xiaodong Gao; Kuntang Shen
Journal:  Cell Commun Signal       Date:  2022-09-08       Impact factor: 7.525

3.  Proteomics provides insights into the inhibition of Chinese hamster V79 cell proliferation in the deep underground environment.

Authors:  Jifeng Liu; Tengfei Ma; Mingzhong Gao; Yilin Liu; Jun Liu; Shichao Wang; Yike Xie; Ling Wang; Juan Cheng; Shixi Liu; Jian Zou; Jiang Wu; Weimin Li; Heping Xie
Journal:  Sci Rep       Date:  2020-09-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.